Skip to main content
. 2023 Jun 9;9(23):eadh1736. doi: 10.1126/sciadv.adh1736

Fig. 5. In vivo evaluation of the antitumor effect of ZIF-67@DOX-TPP nanorobots using a subcutaneous tumor model.

Fig. 5.

(A) Schematic of the mouse model that bears subcutaneous T24 bladder tumor and the following treatment protocol. (B) The tumor growth kinetics of tumor-bearing mice that were treated with various intratumoral injections, including PBS, ZIF-67, DOX-TPP, ZIF-8@DOX-TPP, ZIF-67@DOX, and ZIF-67@DOX-TPP nanorobots, over the treatment process (n = 5; means ± SEM). (C) Excised tumor weights from mice at the end of treatment with nanorobots and other control groups (n = 5; means ± SD). (D) Body weight changes of tumor-bearing mice that were treated with nanorobots and other control groups over the treatment process (n = 5; means ± SEM). (E) Representative images of hematoxylin and eosin (H&E), terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick end labeling (TUNEL), and Ki67 staining of resected tumor tissues from mice that were administrated with nanorobots and other control groups. Scale bars, 100 μm. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; one-way ANOVA.